SOLICITATION NOTICE
A -- Rapid Influenza A+B diagnostic test
- Notice Date
- 3/17/2016
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, U.S. Naval Medical Research Unit - 6 Peru, Unit 3230 Box 343, American Embassy, DPO AA 34031-0343, Lima, Non-U.S., 34031-0343, Peru
- ZIP Code
- 00000
- Solicitation Number
- N44852QUIDELCORPORATION
- Archive Date
- 4/9/2016
- Point of Contact
- Genaro M Vasquez, , Javier B. Gil,
- E-Mail Address
-
genaro.m.vasquez.fn@mail.mil, javier.b.gil.fn@mail.mil
(genaro.m.vasquez.fn@mail.mil, javier.b.gil.fn@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- The U.S. Naval Medical and Research Unit No. 6 (NAMRU-6) is looking for a rapid Influenza A+B diagnostic test for qualitative detection of influenza type A and B with high sensibility to detect Influenza A (H1N1) pdm09, A (H1N1) and A (H3N2), and Influenza B antigens directly from nasal swab, nasopharyngeal swab, nasal aspirate, and nasal wash specimen. This test is not intended to detect influenza C antigens. The kits should not need freeze and be stable at a temperature range of 15-30 °C. The rapid test kit must include individually packaged test strips with mouse monoclonal anti - influenza A and anti - influenza B antibodies, extraction reagent solution: vials with 340μl of salt solution, extraction tubes, lyophilized buffer with detergents and reducing agents, disposable droppers, sterile nasal swabs, positive influenza type A control swab: swab coated with non -infectious recombinant influenza A antigen, positive influenza type B control swab: swab coated with non -infectious recombinant influenza B antigen, negative control swab: swab coated with formalin-inactivated, non-infectious Streptococcus C antigen, and a detailed procedure card. If capable sources are not identified through this notice, then NAMRU 6 intends to award a sole source contract under the authority of 13.106-1(b)(i) to Quidel Corporation. QuickVue Influenza A+B Test manufactured by Quidel Corporation provides the Influenza A+B rapid test that meets our requirements. Quidel Corporation is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people through the development of diagnostic solutions that can lead to improved patient outcomes. The core competences and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development. Their products include: lateral flow (infectious diseases and reproductive health), direct fluorescent antibodies (with expertise in infectious disease and virology), micro-titer production (with a focus on bone and complement pathway markets), fluorescent immunoassay products (Sofia); and molecular diagnostic products including the world's first FDA- cleared handheld molecular device, AmpliVue. This pre-solicitation is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability statements are due by 12:00 PM Local Time, 25 March, 2016. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: genaro.m.vasquez.fn@mail.mil. Please use subject line "N44852QUIDELCORPORATION". Contracting Office Address: 3230 Lima Pl, Washington DC, 20521 United States Primary Point of Contact.: Martin Vasquez genaro.m.vasquez.fn@mail.mil
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/2181ae4beed206335f942818e5a8ab0f)
- Record
- SN04053689-W 20160319/160317234742-2181ae4beed206335f942818e5a8ab0f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |